Phase II
All evaluable patients experienced tumor shrinkage
67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures
A statistically superior mucosal immune response providing a first line of defense against infection
Part 1 top-line data of the NOX-A12 trial to be presented at the September ‘Fourth International Cancer Immunotherapy Conference’
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
Shares of Paris-based Abivax have shot up more than 8 percent this morning after the company posted positive mid-stage results for its ulcerative colitis treatment, ABX464.
Shares of Synlogic, Inc. are climbing this morning after the New York Times highlighted the company’s proprietary synthetic biotics being used to treat patients with PKU. The company also released positive interim data from an ongoing study of its PKU treatment.
Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
PRESS RELEASES